In an era where the technological frontier is often dominated by the dazzling rise of Artificial Intelligence, with its unicorns routinely securing valuations in the tens and hundreds of billions of dollars, biotech startups, by contrast, operate in a different arena. They don’t typically compete for the same gargantuan funding rounds that capture mainstream headlines. Yet, beneath the surface of the AI frenzy, the biotech sector is quietly, but consistently, generating M&A outcomes that are remarkably robust, often eclipsing historic standards in their value and reliability. This steady stream of strategic acquisitions underscores a fundamental truth about the life sciences: innovation in health is a perennial necessity, and established pharmaceutical giants are willing to pay handsomely for promising breakthroughs.

Over the past two calendar years, a significant financial commitment from acquirers has been observed, totaling more than $38 billion dedicated to purchasing venture-backed companies within Crunchbase’s biotech industry categories. This figure represents a substantial investment in the future of medicine, signaling confidence in the innovative pipelines being developed by these nascent firms. And the momentum shows no signs of waning in the current year. So far, 2026 is off to a brisk and promising start, punctuated by major pharmaceutical players making significant moves. A prime example is Eli Lilly, a global pharmaceutical powerhouse, which recently agreed to pay up to $2.4 billion for Orna Therapeutics. Orna, a pioneering startup, is at the forefront of engineering immune cells directly within the body (in vivo), a revolutionary approach that promises to transform the landscape of cell therapies.

According to comprehensive data compiled by Crunchbase, the years 2025 and 2024 stand out as two of the strongest on record for biotech M&A activity. While the industry hasn’t quite reached the unprecedented peak seen in 2021 – a period often characterized by a confluence of factors including the pandemic-driven surge in biotech interest, abundant liquidity, and low interest rates – it has demonstrably moved well past the subsequent low point. This recovery and sustained activity indicate a sector that has found its footing and is delivering tangible value through strategic consolidations. The M&A landscape in biotech is not merely recovering; it’s demonstrating a mature and consistent pattern of value creation, driven by fundamental industry needs and groundbreaking scientific advancements.

The Strategic Imperative Behind Big Pharma’s Shopping Spree

The sustained vigor in biotech M&A is not coincidental; it’s deeply rooted in the strategic imperatives of large pharmaceutical companies. Many global pharma giants are facing what is often referred to as the "patent cliff," where blockbuster drugs that have generated billions in revenue are losing their patent protection, opening the door to generic competition. This impending loss of revenue creates an urgent need to replenish their pipelines with novel therapies and innovative platforms. Biotech startups, with their specialized focus, agile research methodologies, and cutting-edge discoveries in areas like gene therapy, cell therapy, RNA therapeutics, and targeted oncology, are perfectly positioned to fill this innovation gap.

These acquisitions are not just about buying revenue; they are about acquiring future growth drivers, scientific expertise, intellectual property, and often, entire technological platforms. The integration of these smaller, innovative companies allows big pharma to diversify their portfolios, gain access to new therapeutic modalities, and accelerate their presence in emerging fields of medicine. Furthermore, the often lengthy and capital-intensive nature of drug development, coupled with stringent regulatory hurdles, makes acquiring clinical-stage assets from startups a more de-risked and potentially faster path to market than initiating all research internally. This strategic alignment between the innovation needs of large pharma and the capital needs of biotech startups forms the bedrock of the robust M&A environment we are currently witnessing.

Largest Deals Highlight Key Therapeutic Areas

A closer look at the largest deals in recent quarters reveals the specific therapeutic areas and technological approaches that are commanding premium valuations. Since last year, at least nine funded U.S. biotech companies have been sold in transactions valued at $1 billion or more, including potential milestone payments. Using Crunchbase data, a clear picture emerges of where the most significant investments are being made.

The single largest deal involved Johnson & Johnson’s purchase of Halda Therapeutics, a developer of innovative targeted oral therapies for solid tumors, for a substantial $3.05 billion in cash late last year. J&J’s acquisition highlighted its particular interest in augmenting its robust oncology portfolio, specifically by adding Halda’s clinical-stage oral therapy for prostate cancer. Prostate cancer remains a significant area of unmet medical need, and an oral therapy offers distinct advantages in terms of patient convenience and adherence compared to injectable treatments. This deal underscores the value placed on late-stage assets with clear clinical potential in high-impact disease areas.

Following closely, the next two biggest acquisitions both fell within the cutting-edge area of in vivo therapeutics. This revolutionary approach aims to enable a patient’s own body to generate cell therapies that can treat underlying diseases, moving beyond the traditional method of engineering cells outside the body (ex vivo) and re-infusing them.

One such acquisition was Eli Lilly’s aforementioned purchase of Orna Therapeutics, based in Watertown, Massachusetts. Orna had previously garnered significant venture funding, accumulating over $320 million from prominent lead backers including Merck, F2 Ventures, and MPM Capital. Orna’s technology centers around circular RNA (circRNA), which offers potential advantages over linear mRNA, such as increased stability and longer protein expression. Lilly’s strategic rationale for this acquisition aligns with its broader focus on immunology and advanced therapeutic modalities, seeking to leverage Orna’s platform to develop next-generation cell therapies with enhanced efficacy and fewer logistical challenges.

The other major acquisition in this space was AbbVie’s mid-2025 acquisition of Capstan Therapeutics. Capstan, a clinical-stage biotech, is dedicated to developing targeted in vivo RNA technologies, with an initial focus on autoimmune diseases. AbbVie agreed to pay up to $2.1 billion in cash to acquire the San Diego-based startup, which had previously secured $340 million in venture funding. AbbVie, with its strong heritage in immunology (most notably with Humira), is strategically positioning itself for future growth as key patents expire. Capstan’s technology offers a pathway to precisely deliver RNA therapeutics to specific cell types within the body, potentially revolutionizing the treatment of chronic autoimmune conditions with greater specificity and reduced systemic side effects. These two deals underscore a strong investor and acquirer interest in the transformative potential of in vivo gene and cell therapy approaches.

A More Nuanced Picture: Funding Share Slides, IPO Volume Stagnates

While the M&A landscape for biotech presents a picture of robust activity and significant exits, the overall funding and IPO environment for the sector tells a more nuanced story. The industry is indeed generating large acquisition outcomes, but other metrics suggest a more constrained capital market for earlier-stage companies and those seeking public market debuts.

Last year, for instance, less than 9% of all U.S. startup funding was directed towards companies categorized within Crunchbase’s biotech sectors. This represents the lowest share in years and is largely a direct consequence of the immense capital flows pouring into other, currently "hotter" sectors, most notably generative AI. The allure of AI’s perceived rapid scalability, broad applicability, and potentially faster returns has diverted investor attention and capital away from biotech, which typically involves longer development timelines, higher regulatory hurdles, and more specialized scientific expertise.

However, when examining total funding in absolute terms, biotech appears more stable, rather than in a sharp decline. In 2025, just over $25 billion was invested in U.S. startups within the space, a figure that remained roughly flat year over year. While this indicates a resilient core of investment, it also highlights a lack of explosive growth, contrasting sharply with the exponential funding surges seen in the AI domain. This stability suggests that while investors are more selective, they recognize the foundational importance and long-term value proposition of biotech.

The IPO market, traditionally a key exit pathway for biotech companies, remains significantly weaker than historical norms. Last year, Crunchbase data revealed that only 21 biotech, pharma, or medical device companies went public, marking the lowest number in years. This downturn in IPO activity can be attributed to several factors: volatile public markets, higher interest rates making private capital more attractive, increased scrutiny from public investors, and a general shift in investor sentiment following a period of high-volume but sometimes underperforming biotech IPOs.

So far this year, the IPO landscape shows only modest improvement, with just four debuts recorded. A notable recent event was the debut of Eikon Therapeutics this month, a developer of cancer therapies recently valued around $900 million. While a significant valuation, Eikon’s IPO in a quiet market underscores that only the most compelling science and advanced pipelines are currently able to attract public market interest. The general trend suggests that M&A has become the more reliable and often preferred exit strategy for many venture-backed biotech companies and their investors.

Not a Slump, Not a Boom: A Sustainable Path Forward

Ultimately, the composite picture painted by biotech funding and exit data is one of a sector that is neither experiencing a dramatic boom nor suffering a protracted slump. It resides in a middle ground – a state of consistent viability. This might not be the most thrilling narrative for those seeking headline-grabbing valuations or rapid-fire public listings, but it represents a highly sustainable and productive environment for innovation, investment, and ultimately, patient benefit.

For founders in biotech, this environment emphasizes the critical importance of strong scientific rigor, clear clinical development pathways, and a strategic alignment with the therapeutic areas and technological needs of potential acquirers. The focus shifts from simply raising large rounds to demonstrating tangible progress and derisking assets to make them attractive targets for strategic M&A.

For investors, while the patience required for biotech investments remains substantial, the reliable M&A outcomes offer compelling evidence of significant, albeit longer-term, returns. This consistency provides a crucial counterbalance to the more speculative ventures in other tech sectors, appealing to investors seeking fundamental value creation in an essential industry. The ongoing "patent cliff" faced by large pharmaceutical companies, coupled with their robust cash reserves and an insatiable demand for novel therapies, suggests that the strategic imperative for M&A will continue to drive this market for the foreseeable future.

The current state of biotech M&A reflects a healthy ecosystem where innovation is consistently rewarded. It’s a testament to the fact that even without the meteoric valuations of AI unicorns, the pursuit of groundbreaking medical solutions reliably delivers substantial and impactful exits, ensuring that vital progress in health and medicine continues unabated.